James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• James Edgemond, CFO of United Therapeutics, sold 10,000 shares on April 9 at $577.89 under a pre-arranged Rule 10b5-1 plan, leaving him with 18,876 shares (a 34.63% reduction in his holdings).
• Edgemond has executed five other 10,000-share sales since March 23 — 60,000 shares sold in total for roughly $33.5 million in proceeds.
• United Therapeutics trades near $571.73 with a market cap of about $25.1B, recently posted an EPS beat, and has an analyst consensus of "Moderate Buy" with an average target of $601.50.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $577.89, for a total transaction of $5,778,900.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $10,908,251.64. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond also recently made the following trade(s):

• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Trading Down 0.5%

NASDAQ UTHR traded down $3.04 during trading on Friday, hitting $571.73. 417,925 shares of the company traded hands, compared to its average volume of 498,630. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $607.89. The business has a fifty day simple moving average of $514.63 and a 200 day simple moving average of $483.21. The company has a market capitalization of $25.06 billion, a P/E ratio of 20.49, a PEG ratio of 1.67 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the company posted $6.19 EPS. The firm's revenue was up 7.4% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of UTHR. Torren Management LLC bought a new stake in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management lifted its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC boosted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the fourth quarter valued at about $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on UTHR shares. Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. TD Cowen raised their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research note on Monday, March 30th. Bank of America boosted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 31st. Finally, Morgan Stanley upped their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the company an "equal weight" rating in a report on Friday. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $601.50.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.